市场变化对吸入器的下游影响:对慢性肺病患者的影响
Joyce A Baker1, Mitzi L Cardona2, Laney D Brennan3
1Breathing Institute, Children's Hospital Colorado, Aurora, Colorado. joyce.baker@childrenscolorado.org.
Respiratory care
|October 25, 2024
概括
由于成本上升和市场变化,对COPD和喘等慢性肺部疾病的吸入药物的获取具有挑战性. 患者和医疗服务提供者面临着影响治疗坚持和适当处方呼吸道药物的障碍.
科学领域:
- 肺部病理学 肺部病理学
- 卫生经济学 卫生经济学
- 制药政策 制药政策
背景情况:
- 慢性阻塞性肺病 (COPD) 和喘影响全球超过5.45亿人.
- 慢性肺病的年度医疗保健费用在欧盟超过3800亿欧元,在美国超过250亿美元.
- 患者会承担相当大的自付费用,在美国,平均每人4000美元.
研究的目的:
- 审查获得慢性肺部疾病的吸入药物的挑战.
- 分析市场变化对药物可用性和提供者处方的影响.
- 确定患者和医疗保健提供者在呼吸道吸入器方面面临的障碍.
主要方法:
- 从2005年到2024年的英语出版物的综合文献搜索.
- 根据关键词选择了172篇同行评审的文章.
- 包括55篇相关的同行评审文章和38篇专家作者的行业报告.
主要成果:
- 由于成本上升,仿制药问题和保险表单等问题,患者面临挑战.
- 非医疗转换和药物短缺进一步复杂化了获得基本呼吸道治疗的机会.
- 医疗服务提供者面临的行政负担,失去了患者的信任,以及处方限制.
结论:
- 市场动态和成本控制策略为慢性肺部疾病的吸入药物提供了重大障碍.
- 这些挑战会对治疗的坚持和提供者处方最佳疗法的能力产生负面影响.
- 解决这些问题对于改善COPD和喘管理患者的结果至关重要.
相关概念视频
Inhaled Medications
237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
Drugs Used in Lower Respiratory Disorders: Overview
353
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K


